Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Receivables (2019 - 2026)

C4 Therapeutics has reported Receivables over the past 8 years, most recently at $2.9 million for Q1 2026.

  • For Q1 2026, Receivables fell 64.09% year-over-year to $2.9 million; the TTM value through Mar 2026 reached $2.9 million, down 64.09%, while the annual FY2025 figure was $2.4 million, 22.6% down from the prior year.
  • Receivables for Q1 2026 was $2.9 million at C4 Therapeutics, up from $2.4 million in the prior quarter.
  • Over five years, Receivables peaked at $13.6 million in Q1 2024 and troughed at $500000.0 in Q3 2023.
  • A 5-year average of $4.1 million and a median of $2.2 million in 2025 define the central range for Receivables.
  • Biggest five-year swings in Receivables: crashed 74.23% in 2022 and later soared 2475.57% in 2024.
  • Year by year, Receivables stood at $1.5 million in 2022, then surged by 701.02% to $11.8 million in 2023, then tumbled by 73.71% to $3.1 million in 2024, then fell by 22.6% to $2.4 million in 2025, then rose by 20.07% to $2.9 million in 2026.
  • Business Quant data shows Receivables for CCCC at $2.9 million in Q1 2026, $2.4 million in Q4 2025, and $6.5 million in Q3 2025.